Nursing Care and Management of a Rare Case of Aggressive High-Grade Urothelial Carcinoma Transforming into Enteric-Type Adenocarcinoma: A Case Report
DOI:
https://doi.org/10.31674/mjn.2026.v17i03.027Abstract
Bladder cancer, a malignancy with high morbidity and mortality, predominantly affects older adults, with urothelial carcinoma as the most common histological type. However, enteric-type adenocarcinoma arising from high-grade urothelial carcinoma is an exceptionally rare and aggressive variant. This report notes the details of the case of a 44-year-old woman diagnosed at a rural hospital. She presented with hematuria and frequent micturition, leading to a diagnosis of high-grade urothelial carcinoma with villoglandular differentiation. Despite multiple chemotherapy cycles (gemcitabine-carboplatin, followed by Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or MVAC), the tumor progressed. Imaging revealed extensive invasion, necessitating radical anterior exenteration, including cystectomy, hysterectomy, and ileal conduit construction. Histopathology confirmed transformation into enteric-type adenocarcinoma with perineural and lymphovascular invasion but no lymph node metastases. Adjuvant radiotherapy was administered to mitigate recurrence risk. This case points out the obstacles to managing aggressive bladder carcinoma with histological transformation and highlights the need for a multimodal treatment strategy. Individualized approaches integrating surgery, chemotherapy, and radiotherapy are crucial. Further research is needed to establish standardized protocols and identify biomarkers for early detection and targeted therapy.
Keywords:
Chemotherapy, Enteric-type Adenocarcinoma, Radiotherapy, Urothelial CarcinomaDownloads
References
Andreatos, N., Iyer, G., & Grivas, P. (2020). Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. Cancer Treatment and Research Communications, 25, 100179. https://doi.org/10.1016/j.ctarc.2020.100179
Danzig, M. R., Mallin, K., McKiernan, J. M., Stadler, W. M., Sridhar, S. S., Morgan, T. M., Bochner, B. H., & Lee, C. T. (2018). Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer, 124(12), 2507–2514. https://doi.org/10.1002/cncr.31372
DeGeorge, K. C., Holt, H. R., & Hodges, S. C. (2017). Bladder cancer: diagnosis and treatment. American Family Physician, 96(8), 507-514. https://www.aafp.org/pubs/afp/issues/2017/1015/p507.pdf
Gandhi, J., Chen, J. F., & Al-Ahmadie, H. (2022). Urothelial carcinoma : Divergent differentiation and morphologic subtypes. Surgical Pathology Clinics, 15(4), 641-659. https://doi.org/10.1016/j.path.2022.07.003
Hussain, M. H., Wood, D. P., Bajorin, D. F., Bochner, B. H., Dreicer, R., Lamm, D. L., ... & Dinney, C. P. (2009). Bladder cancer: narrowing the gap between evidence and practice. Journal of Clinical Oncology, 27(34), 5680-5684. https://doi.org/10.1200/JCO.2009.23.6901
Kwon, W.-A., Seo, H. K., Song, G., Lee, M.-K., & Park, W. S. (2025). Advances in therapy for urothelial and non-urothelial subtype histologies of advanced bladder cancer: from etiology to current development. Biomedicines, 13(1), 86. https://doi.org/10.3390/biomedicines13010086
Leslie, S., Soon-Sutton, T., & Aeddula, N. (2024). Bladder cancer. StatPearls. http://www.ncbi.nlm.nih.gov/books/NBK536923/
Magi-Galluzzi, C., Falzarano, S. M., & Zhou, M. (2008). Urothelial carcinoma and its variants. Surgical Pathology Clinics, 1(1), 159-209. https://doi.org/10.1016/j.path.2008.07.004
Park, J. C., Citrin, D. E., Agarwal, P. K., & Apolo, A. B. (2014). Multimodal management of muscle invasive bladder cancer. Current Problems in Cancer, 38(3), 80-108. https://doi.org/10.1016/j.currproblcancer.2014.06.001
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020). Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews, 86, 102019. https://doi.org/10.1016/j.ctrv.2020.102019
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 The Malaysian Journal of Nursing (MJN)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.































